Current:Home > NewsRare birdwing butterflies star in federal case against NY man accused of trafficking insects -EliteFunds
Rare birdwing butterflies star in federal case against NY man accused of trafficking insects
View
Date:2025-04-16 13:22:54
NEW YORK (AP) — Birdwing butterflies are among the rarest and largest to grace the planet, their 10-inch wingspans flapping through the rainforests of Southeast Asia and Australia. Their sheer size can make them hard to miss.
But the U.S. Attorney’s Office in Brooklyn says Charles Limmer made tens of thousands of dollars over the past year by illegally trafficking scores of flying insects, including endangered birdwings — whose numbers have fallen because of diminishing habitat and illegal poaching.
The six-count indictment against Limmer, 75, accuses him of working with overseas collaborators to smuggle some 1,000 lepidoptera, including some of the rarest and most endangered moths and butterflies in the world.
Federal authorities in New York say the Long Island man smuggled dried specimens of the species, circumventing U.S. laws by labeling shipments as “decorative wall coverings,” “origami paper craft” and “wall decorations.”
Attempts to reach Limmer by phone and email were unsuccessful.
Federal law prohibits the commercial export or import of wildlife without permission from the U.S. Fish and Wildlife Service. Additional authorization would need to be secured for endangered species, as part of an international partnership to protect wildlife from trafficking.
Limmer previously had a federal license to import and export wildlife, but it was suspended in October 2022.
Since then, the indictment alleges, Limmer illegally imported and exported more than $200,000 worth of shipments.
An eBay page of a seller going by “limmerleps” shows the account had made more than 4,600 sales on the shopping platform, many of the most recent sales were moths and butterflies. There were two birdwing specimens currently on sale and two were sold over the past year, according to the website.
An Etsy page connected to a seller going by the name “Limmer” had four ads for birdwings still advertised on Wednesday, including featuring a collection of five specimens with an asking price of $133.
The indictment also seeks to force Limmer to give up his collection of some 1,000 butterflies, moths and other insects prosecutors say he illegally procured from overseas.
veryGood! (4157)
Related
- What to watch: O Jolie night
- Shop the Top Aluminum-Free Deodorants That Actually Work
- Today’s Climate: May 12, 2010
- Today’s Climate: May 12, 2010
- Vance jokes he’s checking out his future VP plane while overlapping with Harris at Wisconsin airport
- Joe Manchin on his political future: Everything's on the table and nothing off the table
- Pfizer asks FDA to greenlight new omicron booster shots, which could arrive this fall
- Carbon Pricing Reaches U.S. House’s Main Tax-Writing Committee
- Travis Hunter, the 2
- The Book of Charlie: Wisdom from a centenarian neighbor
Ranking
- Blake Lively’s Inner Circle Shares Rare Insight on Her Life as a Mom to 4 Kids
- Over-the-counter hearing aids will bring relief, but with some confusion
- Late-stage cervical cancer cases are on the rise
- Woman dead, 6 others hurt in shooting at Chicago memorial
- Buckingham Palace staff under investigation for 'bar brawl'
- Encore: An animal tranquilizer is making street drugs even more dangerous
- Today’s Climate: May 17, 2010
- You'll Flip a Table Over These Real Housewives of New Jersey Season 13 Reunion Looks
Recommendation
Elon Musk's skyrocketing net worth: He's the first person with over $400 billion
House Votes to Block U.S. Exit from Paris Climate Accord, as Both Parties Struggle with Divisions
Get a $39 Deal on $118 Worth of Peter Thomas Roth Skincare Products
Today’s Climate: May 19, 2010
'Kraven the Hunter' spoilers! Let's dig into that twisty ending, supervillain reveal
How can we help humans thrive trillions of years from now? This philosopher has a plan
Maurice Edwin James “Morey” O’Loughlin
What's behind the FDA's controversial strategy for evaluating new COVID boosters